International Journal of Primary and Critical Care, 2024,
Vol. 02, Iss. 02, S. No. 033, pp. 9-17
ISSN (Online): 2584-2188

Comprehensive Management of Hepatocellular Carcinoma: Epidemiology, Prevention, Diagnosis and Therapeutic Advances

Asadullah Muhammad Hossain Saad[1], Md. Kabir Uddin Sikder[2]

[1]Assistant Manager, Power and Engineering, East Coast Group (Omera Renewable Energy Limited), Dhaka, Bangladesh

[2]Professor, Department of Physics, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh

[1]shadshihab200@gmail.com, [2]kabirsikder@juniv.edu

Abstract

Hepatocellular carcinoma (HCC) is a major worldwide health problem with increasing incidence and mortality. This article reviews the epidemiology, prevention, diagnosis, and treatment of HCC. In this review, we consider the important risk factors of HCC, such as viral hepatitis, non-alcoholic fatty liver disease, and alcohol, taking particular notice of their prevalence in different global areas. Opinions on preventive strategies such as vaccination against hepatitis B virus and surveillance programs for high-risk populations are recorded. In conjunction, this review details current diagnostic modalities, including imaging techniques (ultrasound, CT, and MRI) and serum biomarkers (AFP), as well as the limitations associated with each. These topics will move from surgical resection and liver transplantation to locoregional, systemic therapies, along with a focus on the latest developments in targeted therapy and immunotherapy. Although there have been positive advances in HCC management, the early Detection and successful treatment of advanced-stage disease still pose significant challenges. The ultimate goals of future research in this area may be to develop new therapeutic agents and improve the accuracy of diagnostic imaging based on disease biology for personalized medicine.

Keywords

Hepatocellular carcinoma, Liver cancer, Viral hepatitis, Hepatitis B Virus, Hepatitis C Virus, Non-alcoholic fatty liver disease

*Corresponding Author	How to Cite this Article	To browse

Asadullah Muhammad Hossain Saad, Assistant Manager, Power and Engineering, East Coast Group (Omera Renewable Energy Limited), Dhaka, Bangladesh

Saad AMH, Sikdhar KU. Comprehensive Management of Hepatocellular Carcinoma: Epidemiology, Prevention, Diagnosis and Therapeutic Advances. Int. J. Primary Crit. Care. 2024; 2(2): 9-17.

DOI: https://doi.org/10.54060/a2zjournals.pcc.33

Received	Accepted	Online First	Published
2024-01-01	2024-07-01	2024-07-25	2024-09-30

Funding
Nil

Ethical Approval
Nil

1. Introduction

Hepatocellular carcinoma, one of the most common primary liver cancers, is an important global health problem (BAYNES and DOMINICZAK) [4]. HCC accounts for 85-90% of primary liver cancers and contributes to a substantial cancer burden worldwide in terms of morbidity as well as mortality (Wing and Cheung)(Roberts, R, Lewis) [23] [18]. The past several decades have witnessed the growing tolerance of environmental etiological factors such as viral hepatitis, nonalcoholic fatty liver disease, and alcoholic liver disease, which drive HCC incidence, rendering it a rising trend (Roberts, R, Lewis) [18]. Coinciding with increasing incidence, similar trends in mortality rates further establish HCC as the second most deadly cancer worldwide (Luo et al.) [15].



Figure 1. The striking parallel geographical distribution of the incidence of chronic hepatitis B virus infection and that of hepatocellular carcinoma. (M.C. Kew) [25]

The management of HCC is diverse and consists of prevention, surveillance for early Detection, and a range of therapeutic options. Realistic prevention strategies include the vaccination for hepatitis B virus, as well as interventions to decrease excessive alcohol use and promote harm reduction policies alongside targeted measures both in the clinical arena, including NALFD. For people at high risk of liver cancer, such as anyone with cirrhosis of the liver, finding it early is critical to having a better outcome. The treatment strategy of HCC was classified from the curative pursuance (surgical resection and liver trans-

plantation), locoregional therapies like transarterial chemoembolization (TACE) and radiofrequency ablation (RFA), to systemic targeted therapy or immunotherapy (Liu et al.) [13].

This review provides a comprehensive update on the current knowledge and recent developments in HCC treatment. In the next section, we will delve into HCC epidemiology: its geographical spread worldwide, associated risk factors, and evolving trends. We will also review the control of EV-enterovirus (that includes prevention, diagnostic modalities, and therapeutic approaches), focusing on discoveries or upcoming tasks. The intention was to provide a comprehensive overview of HCC management, focusing on interdisciplinary strategies for this intricate disease.

2. Epidemiology

The epidemiology of hepatocellular carcinoma is complex and shows wide geographic variation (McGlynn, A, Katherine) [14]. Awareness of these patterns is essential to effective prevention and management.

2.1. Global and Regional Incidence and Prevalence

Worldwide, the incidence and prevalence of HCC also differ widely. In descending order, East Asia and Sub-Saharan Africa (Roberts, R, Lewis) [18with high disease burden, contrasted to areas of low incidence like North America and Western Europe (Alan P. Venook) [9]. Around 85% of HCC happens in low- and middle-income countries (Roberts, R, Lewis) [18Geographic disparities are accounted for by the prevalence of underlying risk factors (such as viral hepatitis, aflatoxin exposure), socioeconomic conditions, and access to health care (Alan P. Venook) [9].

2.2. Major Risk Factors for Hepatocellular Carcinoma

Chronic hepatitis B and C infections are responsible for a substantial burden of HCC internationally (Roberts, R, Lewis)(Moon et al.)[18] [16]. Molecular genetic screenings revealed the presence of viruses diagnosed as human papilloma, which are commonly found in Asia and Africa (Roberts, R, Lewis) [18]. A long latent period is important when planning screening antecedents to clear carcinogenic factors such as chronic viral hepatitis (which leads to HCC through chronic inflammation and liver fibrosis/cirrhosis (Soriano and Friedman) [20].

Non-alcoholic Fatty Liver Disease (NAFLD) is becoming a common risk factor for HCC, especially in developed countries (Kim et al.)(Welzel et al.) [11] [22]. NAFLD can progress to nonalcoholic steatohepatitis, which is a major risk factor for HCC development (Kim et al.) [11]. There are specific challenges in diagnosing and managing NAFLD-related HCC.

Alcoholic Liver Disease (ALD) is a major contributor to the development of HCC (Kim et al.) [11]. Chronic inflammation and fibrosis may cause HCC as a progression of alcohol-related liver damage (BAYNES and DOMINICZAK) [4]. Alcohol consumption can synergize with other risk factors, including viral hepatitis, to raise the HCC threat.

Aflatoxin Exposure (AF) dietary exposure to aflatoxin B1, a mycotoxin produced by specific fungi that is one of the most potent naturally-occurring carcinogens and causally related to liver cancer (HCC) (Moon et al.) [16]. Hence, we dissected the correlative relationship between aflatoxin exposure and the incidence of HCC in regions with high dietary intake affected by geographically distributed diseases. HCC is a malignant neoplasm primary of the liver, originating from transformed hepatocytes via cancer-stem cells (Welzel et al.) [22]. They contribute to the promotion of HCC incidence through different pathways, such as insulin resistance, oxidative stress, and iron overload.

2.3. Changing Epidemiological Trends and the Impact of Risk Factor

Epidemiological trends of HCC are changing, with increasing incidence in some regions and shifting risk factor profiles (Thylur RP) [21]. Different risk factors may act together to increase the likelihood of developing HCC. Being aware of these trends also allows care and prevention to be targeted.

3. Prevention

HCC's often-grim prognosis and prevention are paramount in reducing its global burden. Prevention efforts are categorized into primary and secondary prevention.

3.1. Primary Prevention

Hepatitis B vaccination (HBV) is highly effective in preventing HBV infection, a major cause of HCC (De Flora S) [5]. Global implementation of HBV vaccination programs has significantly impacted HCC incidence (Alan P. Venook) [9]. Universal vaccination, particularly in high-prevalence regions, remains crucial.

Screening for chronic HBV and HCV infections is essential. Antiviral therapy reduces HCC risk in individuals with chronic viral hepatitis (Li S) [1]. However, global access to and delivery of antiviral treatment remains challenging.

Lifestyle modifications, including weight loss, dietary changes, and exercise, are crucial in managing NAFLD and reducing HCC risk (Simon TG) [2]. Limiting or abstaining from alcohol is essential for individuals with ALD. Achieving sustained lifestyle changes requires effective behavioral interventions.

Minimizing aflatoxin exposure involves food safety measures, such as proper storage and handling of food crops, regulatory limits on aflatoxin levels, and public awareness campaigns. Implementing these measures can be challenging, especially in resource-limited settings.

3.2. Secondary Prevention

Surveillance programs are crucial for high-risk individuals (e.g., those with cirrhosis, chronic hepatitis B or C, and NAFLD) (Kaya E) [6]. Ultrasound and serum biomarkers like alpha-fetoprotein play a key role in HCC surveillance (Kaya E) [6]. Surveillance programs improve early detection and patient outcomes but face challenges in implementation and maintenance, including cost, access, and patient compliance. Current prevention strategies have shown success, but limitations exist. Vaccination programs, antiviral therapy, lifestyle interventions, and surveillance programs require tailored approaches based on individual risk factors and regional contexts. Ongoing research is essential to develop and refine these strategies.

4. Diagnosis

Diagnosing HCC at an early stage is essential to improving patient prognosis and allowing timely intervention. A detailed insight into the diagnostic modalities employed in clinical practice highlights both the advantages and disadvantages of these assessments.

4.1. Imaging Techniques and Drawbacks

Ultrasound is a non-invasive, cost-effective, and widely available screening tool, especially in high-risk populations (Frenette CT) [19]. Its sensitivity is low, particularly for small tumors, and it is operator-dependent. In detecting small lesions, contrast-enhanced ultrasound (Lee et al.) [12]. Computed Tomography (CT) and Multiphase CT scans provide accurate, detailed anatomical information, and vascular invasion CT does have advantages in characterizing liver lesions and confirming the diagnosis of HCC (Barr et al.) [3]. This process may include radiation exposure and the risk of contrast-induced nephropathy.

Magnetic Resonance Imaging (MRI) (including contrast-enhanced MRI) is high-resolution and can distinguish HCC from other liver lesions (Chan et al.) [8]. MRI has the advantage of displaying tumor characteristics and diagnosing invaded vessels. This process involves costs, availability, and contraindications for some patients with implanted medical devices.

Contrast-enhanced ultrasound (CEUS)is a superior alternative to standard ultrasound for the Detection of small HCC lesions (Chalasani et al.) [7]. It assesses liver tumor vascularity and offers real-time evaluation. This process includes the need for operator time and its lack of availability at all sites.

4.2. Serum Biomarkers

Alpha-fetoprotein (AFP) is a widely used biomarker for HCC (BAYNES and DOMINICZAK) [4]. Nevertheless, it is nonspecific and has limited sensitivity because elevated AFP levels can also be found in other liver diseases. AFP can also be used along with other imaging modalities to help increase diagnostic precision (Frenette CT) [19].

Novel biomarkers such as des-gamma-carboxy prothrombin and Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein may provide enhanced early Detection, prognostication, etc. Further investigation is being done in this arena.

4.3. Histopathological Examination

The biopsy includes a fine-needle aspiration or core biopsy and is required to confirm the diagnosis of HCC when imaging findings alone are equivocal, in addition to elevated serum biomarkers (Brunt, Elizabeth) [10]. Different means of biopsy have risks and benefits. Biopsy provides a measure of grade and other histological characteristics.

4.4. Importance of Early Diagnosis

Early diagnosis is vital for better prognosis and treatment responses. Treatments for HCC include surgical resection (Wing and Cheung) [23] and liver transplantation.

4.5. Diagnostic Algorithm

Current diagnostic algorithms from the American Association for the Study of Liver Diseases and the European Association for the Study of Liver integrate imaging, serum biomarkers, and histopathology to guide appropriate diagnosis. In many of these algorithms, imaging characteristics are integrated with AFP levels and biopsy data to establish diagnosis as well as management.

5. Treatment and Drawbacks

HCC treatment is multimodal, influenced by its stage at presentation, the patient's general health status, and resource availability. Barcelona Clinic Liver Cancer staging system offers a schema for treatment allocation, assisting clinicians in identifying the most applicable therapeutic strategies (Kaya E) [6]. For optimal treatment decision-making, a multidisciplinary team approach is crucial where specialists from hepatology, oncology, surgery, radiology, and pathology collaborate.

5.1. Curative Treatments

Surgical Resection is a curative option for patients with early-stage HCC (Wing and Cheung) [23]. To be considered resettable, a patient must possess adequate liver function and have no evidence of portal hypertension. Resection has potential benefits; however, one must recognize its limitations due to the general risks of recurrence.

Liver Transplantation serves as a curative option for patients with early-stage HCC who are within specific criteria by tumor size and number (Wing and Cheung) [23]. Although transplantation provides advantages, it is also associated with organ availability and restrictions, the need for chronic immunosuppression regimens to maintain graft function, and the risk of recurrence.

5.2. Locoregional Therapies

Drugs work at the hepatic site (the liver) with the goal of preventing tumor growth and thereby prolonging survival in patients who are not considered for curative therapy.

Transarterial Chemoembolization (TACE) is a widely used locoregional therapy for HCC patients in intermediate-stage) (Liu et al.) [13]. The treatment is a combination of chemotherapy and embolization that destroys the blood supply to your tumor. While TACE has many known benefits, it also has drawbacks and possible adverse effects.

Radiofrequency Ablation (RFA) is a minimally invasive technique that uses heat to destroy tumor tissue. It is limited but beneficial in terms of the size and site of the treatable tumor.

Microwave Ablation (MWA) is a thermal ablation similar to RFA in effectivity and security.

Percutaneous Ethanol Injection (PEI) involves injecting ethanol into the tumor to cause necrosis. Used in the treatment of small HCC lesions.

5.3. Systemic Therapies

Therapies work using small molecules that are dispersed throughout the body to attack cancer cells, as opposed to other available drugs, which act on one particular cell and are usually used for late-stage HCC. Targeted therapies, collectively known as Sorafenib, Lenvatinib, Regorafenib, and Cabozantinib, inhibit specific molecular pathways involved in tumor growth and angiogenesis. These therapies may extend survival in patients with advanced HCC, but they can be toxic. Immunotherapy using checkpoint inhibitors like Nivolumab, Pembrolizumab, and atezolizumab is also a type of targeted therapy technique in which the human immune system is employed to control cancer cells. The role of immunotherapy in managing advanced HCC is being defined, offering some promise but also potential risks.

5.4. Treatment Algorithms Based on BCLC Staging

The System Guideline states that the BCLC staging system decides the patient's treatment options and also guides therapy (Kaya E) [6].

6. Future Directions

Although substantive advances have been achieved in the management of HCC, continued progress and development may lead to novel areas for treatment. In this portion, we showcase new modalities and research breakthroughs that are poised to change the face of HCC care.

6.1. Emerging Therapies

New targeted therapies, including those developed in combination with immunotherapies, are being made to enhance treatment efficacy by overcoming the resistance mechanisms. Current research is examining these new agents in clinical trials. This could be manifested through the use of approaches to personalized medicine based on either signs/symptoms or molecular profiling for individualized treatment strategies. A variety of emerging trials have found a potential clinical benefit to the addition of combination therapies, particularly targeting immunotherapy combinations (Liu et al.) [13]. The resistance mechanisms remain largely unsolved, and efforts towards overcoming these resistances are ongoing.

Gene Therapy and Oncolytic Virotherapy are Innovative Treatment Modalities for HCC (Patil et al.) [17]. They have different mechanisms of action. The goal of gene therapy is to change the genes in cancer cells so that these cells die or grow more slowly. In oncolytic virotherapy, a virus selectively infects and kills cancer cells. Here, we discuss challenges and opportunities for the clinical translation of such therapies.

6.2. Research Advancements in Early Detection and Prevention Strategies

Early Detection plays an essential role in preventing early Detection, which would be twofold sensitive and specific diagnostic tools that were able to detect incipient HCC earlier (Simon TG) [2]. These are novel biomarkers, liquid biopsies, and advanced imaging techniques, which, if used, can lead to improved early Detection, thereby facilitating timely intervention. The prog-

nosis is poor, and treatment strategies are largely palliative: for patients with hepatocellular carcinoma (HCC) due to chronic HBV infection, cures are rare as curative treatments are most effective when HCCs can be detected at an early stage.

Research is ongoing in the area of HCC prevention, especially among high-risk populations (De Flora S) [5]. HCC incidence may be reduced by lifestyle modification, antiviral therapies, and chemoprevention. The other big piece is looking at the modifiable risk factors: Viral hepatitis and non-alcoholic fatty liver disease seem to be very large contributors. 6.3. Personalized Medicine Approaches Based on Molecular Profiling

Molecular profiling is now being used more commonly for the characterization of HCC subtypes. Also, it provides potential biomarkers that could be targeted to develop new therapeutic approaches (Zender et al.) [24]. Molecular profiling can help inform treatment decisions and enable the development of targeted therapy. By understanding the molecular features of each tumor, clinicians can make treatment decisions tailored to that patient.

The precision medicine concept recommends treatment strategies that are tailored on an individual basis, e.g., based on the molecular profiles of a patient's tumor type and stage, as well as other health determinants. Challenges and opportunities of precision medicine in HCC care Personalizing treatment regimens may increase the efficiency of treatments and reduce side effects, indicating that precision medicine has vast potential to improve outcomes**.**

7. Conclusions

Advances in the treatment of hepatocellular carcinoma have resulted in better outcomes for patients with this disease. An increasing number of studies have focused on the early surveillance and diagnosis of HCC to diagnose it sooner with timely intervention and potentially curative treatments. The treatment landscape for advanced HCC has been transformed through the development of efficacious locoregional and systemic therapies, as well as the approval of targeted agents and immunotherapies. The Barcelona Clinic Liver Cancer (BCLC) staging system is also a useful working model that helps in making decisions about treatment according to the characteristics of each patient.

To optimize the management of HCC, integrated strategies that include prevention, early diagnosis, and personalized treatment are crucial. Targeted prevention strategies should be targeted at modifiable risk factors such as viral hepatitis and non-alcoholic fatty liver disease by vaccination, antiviral therapies, and lifestyle. One of the reasons that make it necessary to detect HCC as early as possible is through surveillance programs and improved diagnostic tools (perfectly when curative treatments are feasible). Molecular profiling-based precision medicine strategies promise to display the treatment needs of the individual patients in such a way that efficacy is maximized, and toxicity or adverse effects are avoided.

These improvements notwithstanding, HCC remains a formidable disease, and continued research is needed to further enhance patient outcomes. Further research should include new treatment options, such as targeted immunotherapies, gene therapies, and oncolytic virotherapy. Future studies are still required to improve diagnostic algorithms, discover additional biomarkers for early diagnosis, and develop more effective preventive strategies. This collaboration can help to achieve a world where HCC is not one of the deadliest cancers.

References

1. Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, et al. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med. 2020;9(12):3817. doi: 10.3390/jcm9123817. PMID: 33255794; PMCID: PMC7760293.
2. Simon TG, Chan AT. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. Clin Liver Dis. 2020;24(4):549-76. doi: 10.1016/j.cld.2020.06.002. PMID: 33012445; PMCID: PMC7536356.
3. Barr M, Daniel E, et al. Imaging Techniques for the Diagnosis of Hepatocellular Carcinoma and the Evaluation of Re-

sponse to Treatment. Thieme Med Publ. 2014;34(4):398-414. doi: 10.1055/s-0034-1394140.

4. Baynes JW, Dominiczak MH. Medical Biochemistry. Compressed Edition.
5. De Flora S, Bonanni P. The prevention of infection-associated cancers. Carcinogenesis. 2011;32(6):787-95. doi: 10.1093/carcin/bgr054. PMID: 21436188; PMCID: PMC3314281.
6. Kaya E, Daniel Mazzolini G, Yilmaz Y, Canbay A. Prevention of hepatocellular carcinoma and monitoring of high-risk patients. Hepatol Forum. 2022;3(1):33-38. doi: 10.14744/hf.2021.2021.0033. PMID: 35782375; PMCID: PMC9138915.
7. Chalasani N, et al. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2021;20(1):173-182.e7. doi: 10.1016/j.cgh.2021.08.010.
8. Chan M, et al. HCC screening: assessment of an abbreviated non-contrast MRI protocol. Insights Imaging. 2019;3(1). doi: 10.1186/s41747-019-0126-1.
9. Venook AP, Papandreou C, Furuse J, Ladrón de Guevara L. The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. Oncologist. 2010;15(S4):5–13. doi: 10.1634/theoncologist.2010-S4-05.
10. Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, et al. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocyte differentiation. Hepatology. 2018;68(1):113-26. doi: 10.1002/hep.29789.
11. Kim E, et al. Potential Roles and Key Mechanisms of Hawthorn Extract against Various Liver Diseases. Nutrients. 2022;14(4):867. doi: 10.3390/nu14040867.
12. Lee SG, et al. Robust End-to-End Focal Liver Lesion Detection Using Unregistered Multiphase Computed Tomography Images. IEEE Trans Emerg Top Comput Intell. 2021;7(2):319-29. doi: 10.1109/TETCI.2021.3132382.
13. Liu X, et al. Efficacy and Safety of Transcatheter Arterial Chemoembolization and Transcatheter Arterial Chemotherapy Infusion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Oncol Res. 2017;26(2):231-39. doi: 10.3727/096504017X15051752095738.
14. London TW, Petrick JL, McGlynn KA. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Gut Liver. 2015. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712629/.
15. Luo X, et al. Long Noncoding RNA GATA3-AS1 Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma by Suppression of PTEN, CDKN1A, and TP53. J Oncol. 2019;2019:1389653. doi: 10.1155/2019/1389653.
16. Moon H, et al. High Risk of Hepatocellular Carcinoma Development in Fibrotic Liver: Role of the Hippo-YAP/TAZ Signaling Pathway. Int J Mol Sci. 2019;20(3):581. doi: 10.3390/ijms20030581.
17. Patil A, Mohini S. Hedgehog signaling in human hepatocellular carcinoma. Cancer Biol Ther. 2006;5(1):111-7. doi: 10.4161/cbt.5.1.2379.
18. Roberts LR, Lewis PD, Amadou A, et al. A global view of hepatocellular carcinoma: trends, risk, prevention, and management. Gut Liver. 2019. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813818/.
19. Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes. 2019;3(3):302-10. doi: 10.1016/j.mayocpiqo.2019.04.005. PMID: 31485568; PMCID: PMC6713857.
20. Soriano P, Friedman SL. Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci. 2012;S5(1):217-30. doi: 10.2741/S368.
21. Thylur RP, Roy SK, Shrivastava A, LaVeist TA, Shankar S, Srivastava RK. Assessment of risk factors and racial and ethnic differences in hepatocellular carcinoma. JGH Open. 2020;4(3):351-59. doi: 10.1002/jgh3.12336.
22. Welzel TM, et al. Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States. Am J Gastroenterol. 2013;108(8):1314-21. doi: 10.1038/ajg.2013.160.

23. Wing K, Cheung TT. Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration. J Hepatocell Carcinoma. 2016;4:1-9. doi: 10.2147/JHC.S96085.

24. Zender L, et al. Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach. Cell. 2006;125(7):1253-67. doi: 10.1016/j.cell.2006.05.030.

25. Kew MC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris). 2010;58(4):273-77. doi: 10.1016/j.patbio.2010.01.005.